PRAM1

Across TCGA pan-cancer cohorts, PRAM1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRAM1 data layer compared with 21 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PRAM1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PRAM1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where PRAM1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	1.000	0.498	.017	7	view →
HNSC	DFS	Median	III,IV	0.479	0.745	.003	6	view →
PDAC	OS	Median	All	0.941	0.710	.022	6	view →
CCRCC	OS	Median	All	0.745	0.962	.013	5	view →
UCEC	OS	Median	II,III,IV	1.000	0.628	.013	4	view →
LSCC	OS	Quartile	All	1.000	0.610	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRAM1–LUAD (DFS)

Open the LUAD breakdown →